Pazopanib or sunitinib for metastatic renal-cell carcinoma?

被引：0
|
作者：
Bennet, Neil
机构：
来源：
LANCET ONCOLOGY | 2013年 / 14卷 / 11期
关键词：
D O I：
10.1016/S1470-2045(13)70409-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E442 / E442
页数：1
相关论文
共 50 条
  • [21] METASTATIC RENAL-CELL CARCINOMA
    MCNUTT, MA
    BOLEN, JW
    GOWN, AM
    HAMMAR, SP
    VOGEL, AM
    ULTRASTRUCTURAL PATHOLOGY, 1985, 9 (1-2) : 45 - 49
  • [22] Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan
    Al-Rabayah, Abeer A.
    Sawalha, Razan
    Al Froukh, Rawan Fawzi
    Al-Bawab, Rand
    Jaddoua, Saad M.
    JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH, 2021, 12 (04) : 566 - 573
  • [23] Adjuvant Sunitinib in Renal-Cell Carcinoma REPLY
    Ravaud, Alain
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 893 - 893
  • [24] Sunitinib in renal-cell carcinoma: expanded indications
    Choueiri, Toni K.
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2009, 10 (08): : 740 - 740
  • [25] Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein, David
    Rosenberg, Jonathan E.
    Figlin, Robert A.
    Townsend, Raymond R.
    McCann, Lauren
    Carpenter, Christopher
    Pandite, Lini
    EUROPEAN JOURNAL OF CANCER, 2016, 53 : 96 - 104
  • [26] Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
    Ekenel, M.
    Karabulut, S.
    Cil, I
    Zirtiloglu, A.
    Aydin, E.
    Tural, D.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (01): : 27 - 33
  • [27] Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
    Amdahl, Jordan
    Diaz, Jose
    Sharma, Arati
    Park, Jinhee
    Chandiwana, David
    Delea, Thomas E.
    PLOS ONE, 2017, 12 (06):
  • [28] Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma
    Ebinc, Senar
    Kalkan, Ziya
    Oruc, Zeynep
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (04): : 226 - 234
  • [29] Impact of Metastatic Site in Favorable-Risk Renal Cell Carcinoma Receiving Sunitinib or Pazopanib
    Catalano, Martina
    De Giorgi, Ugo
    Bimbatti, Davide
    Buti, Sebastiano
    Procopio, Giuseppe
    Sepe, Pierangela
    Santoni, Matteo
    Galli, Luca
    Conca, Raffaele
    Doni, Laura
    Antonuzzo, Lorenzo
    Roviello, Giandomenico
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 514 - 522.e1
  • [30] Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma
    Penttila, Patrick
    Rautiola, Juhana
    Poussa, Tuija
    Peltola, Katriina
    Bono, Petri
    CLINICAL GENITOURINARY CANCER, 2017, 15 (03) : 384 - 390
12345